Overview

Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study

Status:
RECRUITING
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is a prospective and single arm clinical study. The goal of this clinical trial is to observe and evaluate the efficacy and safety of Daratumumab/daratumumab and hyaluronidase-fihj in combination with pomalidomide and dexamethasone in the treatment of patients with newly diagnosed AL amyloidosis.
Phase:
NA
Details
Lead Sponsor:
Yongyong MA
Treatments:
daratumumab
darlin protein, Dictyostelium
Dexamethasone
pomalidomide